These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease. Bliddal H; Bech K; Kirkegaard C Horm Metab Res; 1984 Nov; 16(11):602-5. PubMed ID: 6210237 [TBL] [Abstract][Full Text] [Related]
26. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients. Szabó J; Leövey A; Karányi Z; Várvölgyi C; Fórizs E; Herceg L Acta Med Hung; 1989; 46(1):23-30. PubMed ID: 2570399 [TBL] [Abstract][Full Text] [Related]
27. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248 [TBL] [Abstract][Full Text] [Related]
28. Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year. Talbot JN; Duron F; Féron R; Aubert P; Milhaud G J Endocrinol Invest; 1989 Oct; 12(9):589-95. PubMed ID: 2573625 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. Bliddal H; Kirkegaard C; Siersbaek-Nielsen K; Friis T Acta Endocrinol (Copenh); 1981 Nov; 98(3):364-9. PubMed ID: 6170200 [TBL] [Abstract][Full Text] [Related]
30. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis. Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007 [TBL] [Abstract][Full Text] [Related]
31. Clinical significance of elevated labeled TSH binding (LTB) activity in sera of patients with Graves' disease and other thyroid disorders. Akamizu T; Mori T; Ishii H; Yokota T; Nakamura H; Imura H J Endocrinol Invest; 1987 Oct; 10(5):459-64. PubMed ID: 2892876 [TBL] [Abstract][Full Text] [Related]
32. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin. Mukuta T; Tamai H; Oshima A; Morita T; Matsubayashi S; Fukata S; Kuma K Clin Endocrinol (Oxf); 1994 Feb; 40(2):215-9. PubMed ID: 7907955 [TBL] [Abstract][Full Text] [Related]
33. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment. Kasagi K; Iida Y; Konishi J; Misaki T; Arai K; Endo K; Torizuka K; Kuma K Acta Endocrinol (Copenh); 1986 Apr; 111(4):474-80. PubMed ID: 2422860 [TBL] [Abstract][Full Text] [Related]
34. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients. Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435 [TBL] [Abstract][Full Text] [Related]
35. Thyrotrophin binding inhibition by anti-thyrotrophin receptor antibodies in Graves' disease which is not reflected by 1.6 M ammonium sulphate precipitates. de Bruin TW; Van der Heide D; Querido A Clin Endocrinol (Oxf); 1982 Jul; 17(1):77-84. PubMed ID: 6126284 [TBL] [Abstract][Full Text] [Related]
36. The effect of subtotal thyroidectomy with propranolol preparation on antibody activity in Graves' disease. Steel NR; Taylor JJ; Young ET; Farndon JR; Holcombe M; Kendall-Taylor P Clin Endocrinol (Oxf); 1987 Jan; 26(1):97-106. PubMed ID: 3802553 [TBL] [Abstract][Full Text] [Related]
37. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine. Teng CS; Yeung RT; Khoo RK; Alagaratnam TT J Clin Endocrinol Metab; 1980 Jun; 50(6):1005-10. PubMed ID: 6103007 [TBL] [Abstract][Full Text] [Related]
38. Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease. Noh J; Hamada N; Saito H; Oyanagi H; Ishikawa N; Momotani N; Ito K; Morii H J Clin Endocrinol Metab; 1989 Jan; 68(1):107-13. PubMed ID: 2909548 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease. Kasagi K; Iida Y; Hatabu H; Tokuda Y; Arai K; Endo K; Konishi J Acta Endocrinol (Copenh); 1988 Feb; 117(2):173-80. PubMed ID: 2454576 [TBL] [Abstract][Full Text] [Related]
40. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis. Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]